JPMorgan lowered the firm’s price target on Revvity (RVTY) to $96 from $105 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity upgraded to Hold from Sell at Nephron Research
- Revvity’s AI Push Brings Innovation Potential but Heightened Operational, Legal, and Reputational Risks
- Revvity price target raised to $129 from $123 at Baird
- Revvity price target raised to $124 from $120 at TD Cowen
- Revvity price target raised to $118 from $112 at Evercore ISI